ScreenerHero

GRIGRI Bio Inc. Common Stock

NAS · US · Healthcare · Biotechnology · gribio.com
1.650USD-4.62%Mkt Cap: 3.61M $P/E: —

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.61M $
Enterprise Value-8.03M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.96M $
Revenue/Share—
Last Price1.650 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.66
PEG—
EV/EBITDA0.73
EV/Revenue—
P/S—
P/B0.25
EPS (TTM)-2.73
EPS (Forward)-2.54
52W Range
1.3600% of range80.36
52W High80.36 USD
52W Low1.360 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-199.00%
ROA-137.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.19M $
CapEx (TTM)3.00K $
FCF Margin—
FCF Yield-216.26%
Net Debt-10.99M $
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity0.01
Current Ratio14.21
Quick Ratio13.91
Book Value/Sh6.653 USD
Cash/Share6.239 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateJan 26, 2026
Analyst Consensus
Rating—
Target (Mean)21.00 USD
Upside (mean)+1172.7%
Target Range10.00 USD – 32.00 USD
$10.00+1172.7% to mean$32.00
# Analysts2
Ownership
Shares Out.2.19M
Float1.77M
Insiders0.46%
Institutions2.90%
Short Interest
Short Ratio3.2d
Short % Float6.21%
Short % Out.6.21%
Shares Short110.03K
Short (prev mo.)114.89K
Technical
SMA 501.743 (-5.3%)
SMA 2009.642 (-82.9%)
Beta-0.66
S&P 52W Chg18.16%
Avg Vol (30d)274.85K
Avg Vol (10d)775.68K
Technical Indicators
RSI (14)48.9
MACD0.0170
MACD Signal-0.0070
MACD Hist.+0.0240
BB Upper2.015 USD
BB Middle1.601 USD
BB Lower1.187 USD
BB Width51.76%
ATR (14)0.1719 USD
Vol Ratio (20d)0.21x